Human Vascular Endothelial Growth Factor-165 (hVEGF165 ) #8065
We recommend the following alternatives
#
Product Name
Inquiry Info. # 8065
Please see our recommended alternatives.
Product Information
Formulation
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hVEGF165. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Storage
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Product Description
| MW (kDa) | 26 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hVEGF165. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1μg hVEGF165. |
| Activity | The bioactivity of recombinant hVEGF165 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-6 ng/ml. |
| Molecular Formula | Recombinant hVEGF165 contains no "tags" and has a calculated MW of 19,165. DTT-reduced protein migrates as a 24 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 40 kDa protein. The expected amino-terminal APMAE of recombinant hVEGF165 was verified by amino acid sequencing. |
Source / Purification
Recombinant human VEGF165 (hVEGF165) Ala207-Arg371 (Accession #NP_001020539) was expressed in human 293 cells at Cell Signaling Technology.
Background
VEGF165 is the most abundant splice variant of VEGF-A (1,2). VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1). VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.